SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
Cancer is talking. We’re listening.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our machine uses to manage motion and treat solid tumors of any stage disease.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
New molecule to enable RefleXion’s SCINTIX therapy to treat most solid tumors HAYWARD, Calif., and BERLIN, Sept. 20, 2023 – RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop […]
It sounds like the stuff of science fiction: a technology that can detect the biological activity of cancer cells in the body and direct targeted beams of energy to destroy tumors in real-time. That vision is now a reality, and with it, a new day has dawned for cancer care. The milestone moment occurred in […]